Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafasitamab in Pediatric Relapsed/Refractory B-Lineage ALL
2024-511336-28-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tafasitamab in acute lymphoblastic leukemia (ALL), sponsored by University Hospital Tübingen. Primary endpoint: Time to hematological relapse or MRD increase in bone marrow. Planned start Aug 2024; status: authorised.
02
Drugs
tafasitamab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2024-511336-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511336-28-00.